:

Chengwei Peng1, Paul E Oberstein2

  • 1Department of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Chengwei.peng@northwestern.edu.

PubMed
まとめ

臓がんの治療は新しいKRAS阻害剤と免疫療法によって進歩しています 将来の戦略では 標的型療法と 免疫ベースのアプローチを組み合わせて より良い患者の治療結果が得られるでしょう

関連する概念動画

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
128
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K